Physician profile
Bella Wolf
NPI 1366947087
$1,239.70
in general payments reported to CMS, 2019-2025
14 companies · $431 in 2025
The $431 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $148 · 2022: $290 · 2023: $171 · 2024: $199 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $801.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $416.20 | 2022-2025 | Lensx, Rocklatan, Eysuvis |
| Sight Sciences, INC. | $147.88 | 2021 | |
| Harrow Eye, LLC | $95.26 | 2025 | Iheezo |
| Glaukos Corporation | $90.33 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $88.73 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $81.25 | 2024-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $67.99 | 2024-2025 | Miebo |
| Oyster Point Pharma, INC. | $62.77 | 2024 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $50.80 | 2024-2025 | |
| Abbvie INC. | $42.55 | 2025 | |
| Amgen INC. | $30.42 | 2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $26.43 | 2025 | Lipiflow System Activator (Disposable) |
| Abb Con-Cise Optical Group LLC | $21.56 | 2025 | Contact Lens |
| Ocular Therapeutix, INC. | $17.53 | 2025 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bella Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.